Vancouver, BC — July 13, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, announces that it has signed a Master Service Agreement (“MSA”) with Standard Lithium Ltd. (“SLI”). For the first project under this MSA, Telescope will receive funding for one year to evaluate the utilization and sequestration of CO2 within the lithium brine extraction and reinjection processes developed by SLI. This project bolsters Telescope’s “Industries” division, which leverages unique lab automation and analytical capabilities to address process and manufacturing challenges in the chemical industry.
Jason Hein, CEO of Telescope, has previously executed successful projects with SLI and is the inventor of its SiFT lithium carbonate crystallization technology. “Telescope is ideally positioned to understand the process chemistry and technology required to integrate CO2 utilization and sequestration within Standard Lithium’s operations,” he commented. “We are working towards the decarbonization of the lithium supply chain and continuing to strategically deploy Telescope’s tools and expertise across the chemical industry.”
About Standard Lithium
SLI is an innovative technology and lithium development company. SLI’s flagship project is located in southern Arkansas, where it is engaged in testing and proving the commercial viability of lithium extraction from over 150,000 acres of permitted brine operations. The president of SLI, Dr. Andy Robinson, and the CEO, Robert Mintak, are also independent directors of Telescope. However, the MSA is not considered a related party transaction within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, and has been reviewed and approved by Telescope’s independent directors.
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Telescope also applies these toolsets to resolve inefficiencies in industrial process chemistry and manufacturing. Our aim is to bring modern chemical solutions to meet the most serious challenges in health and sustainability.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.
Forward-looking statements in this document include expectations surrounding the use and viability of the intellectual property portfolio held by the Company, the research related to the utilization and sequestration of CO2 within SLI’s operations, and all other statements that are not statements of historical fact.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; the success of the first project conducted with SLI; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Vancouver, BC — June 27, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, announces the creation of “Telescope Automation”, a division of the Company that develops automated systems to accelerate chemical and biopharmaceutical research and development. Telescope Automation is pleased to launch its first product, the Direct Inject Liquid Chromatography (“DILC”) platform, an innovative instrument for real-time, immediate analysis of chemical reactions. The DILC platform fuses Telescope’s proprietary hardware, software, and unique integration know-how with proven sampling technology supplied by an internationally renowned manufacturer of lab instrumentation (the “Sampler Manufacturer”). The Sampler Manufacturer is the global leader in enabling hardware and software technology that accelerates the development of chemical and biological processes.
“We have been engaged by several major global pharmaceutical companies to onboard our DILC platform,” said Jason Hein, Telescope CEO. “Telescope has already leveraged this enabling tool across all our operations, and we are now bringing this to market as an unrivaled capability to address an unmet need in process analytics. The versatility and robustness of our platform surpasses other existing solutions for online chemistry analysis.”
This product launch enables Telescope to capture the fast-developing market opportunity for the DILC system, generate revenue, and establish the Company as a partner of choice for process laboratory tool integration. The commercial deployment and insight provided by DILC technology will highlight, at an industrial scale, the unique combination of skills Telescope provides to support chemical, biopharmaceutical, and manufacturing process development.
About Telescope’s Direct Inject (DILC) Platform
The DILC platform enables rapid, robust online analysis of chemical reactions. Specifically, the system samples batch or continuous processes and automatically quenches, dilutes, and injects the samples into a high- or ultra-performance liquid chromatography (“HPLC” or “UPLC”) instrument. When combined with orthogonal techniques such as spectroscopic analysis, this system provides full, comprehensive profiles of chemical reactions in real time (Figure 1).
The DILC system is fully automated and uses the market leading in-situ sampling probe (sold by the Sampler Manufacturer) to deliver reaction samples to HPLC/UPLC instruments in pseudo-real time. The entire process is controlled through Telescope’s intuitive software for workflow management. The DILC system ensures precise and reproducible samples, especially in heterogeneous and multiphase reactions or reactions at sub-ambient or elevated temperatures and pressures. Furthermore the DILC system eliminates delays in quenching that typically lead to variable results and inaccurate analytical information.
Figure 1. Simplified schematic of Telescope’s DILC system in an online chemical analysis setup.
Telescope’s DILC system provides many advantages in chemical process analysis:
Rapid sampling frequency (the time period between sampling is near-HPLC method run times)
No sample aging (sample is delivered directly to analysis with no exposure to the external environment)
Adjustable dilution supporting a wide range of reaction concentrations
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Telescope also applies these toolsets to resolve inefficiencies in industrial process chemistry and manufacturing. Our aim is to bring modern chemical solutions to meet the most serious challenges in health and sustainability.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.
Forward-looking statements in this document include expectations surrounding the intended operation and use of the DILC platform, the ability of the DILC platform to generate revenue and the commercial viability of marketing the DILC platform to existing pharmaceutical companies, and all other statements that are not statements of historical fact.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; the willingness of existing pharmaceutical companies to adopt and utilize the DILC platform; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Vancouver, BC — April 26, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, announces that in connection with the Company’s annual general meeting of shareholders scheduled to occur on April 28, 2022, management of the Company understands that a nomination from the floor will be made for the election of Henry Dubina as an additional independent director of the Company. The nomination of Mr. Dubina is supported by management and the Company recommends that shareholders vote in favour of the election of Mr. Dubina as a director of the Company.
Mr. Dubina was the president and Strategic Business Unit Head of Mettler-Toledo AutoChem (“MT AutoChem”) between 1999 and his retirement in 2022. As the President and Head of MT AutoChem for over 20 years, he directed the global business from Research & Development, Manufacturing, and Marketing, to Sales and Service. MT AutoChem instruments have been ubiquitously deployed in academia and industry for biopharmaceutical, chemical, and advanced materials applications to accelerate the development of new, high-quality chemical and biological entities and processes. Technology platforms included automation, spectroscopy, sampling systems, particle size and shape measurement and calorimetry, software & machine learning algorithms. Prior to this time, Mr. Dubina developed and directed Applied Systems Inc., into a $15 million provider of in-situ spectroscopy systems (Fourier-transform infrared instruments) and related sampling and software (ReactIR) before its acquisition in 1999 by Mettler-Toledo International, Inc.
Jason Hein, CEO states, “We are looking forward to working with Henry and harvesting some of the valuable knowledge and guidance he brings to the table as we implement our corporate strategies and build on our strong governance.”
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Telescope also applies these toolsets to resolve inefficiencies in industrial process chemistry and manufacturing. Our aim is to bring modern chemical solutions to meet the most serious challenges in health and sustainability.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.
Forward-looking statements in this document include expectations that the shareholders of the Company will elect Mr. Dubina as an additional independent director of the Company, and all other statements that are not statements of historical fact.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Vancouver, BC — March 1, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, is pleased to provide a corporate update summarizing the significant milestones the Company has achieved over the past year of operations. The rapidly growing Company has delivered on the following three milestones that it believes set the foundation for unlocking future value for shareholders:
“In a little over a year, we have established Telescope as a deep tech company applying innovative chemistry technology to challenges in the pharmaceutical industry.” Said Jason Hein, CEO of Telescope. “We have discovered novel, scalable routes to manufacture psilocybin and address a huge unmet need in the treatment of mental health. Beyond this application, we are developing a robust set of technology platforms that accelerate chemistry research by leveraging robotic automation and artificial intelligence. We look forward to building out from this core foundation and deploying our systems to meet the biggest challenges in healthcare and chemical manufacturing.”
1. Established a growing intellectual property portfolio valuable for pharmaceutical manufacturing
One of Telescope’s strategic aims is to capitalize on the demand for the pharmaceutical-grade psychedelic therapeutics that are poised to address a growing US$ 16 billion market in anxiety disorders and depression treatment. While demand is growing, there is currently no regulated safe supply of psilocybin for therapeutic use. The Company has therefore focused on developing proprietary, scalable synthetic processes compatible with current good manufacturing practices (“cGMP”), with a view to sell and/or license this intellectual property to pharmaceutical companies or therapeutic providers.
Telescope has built out an intellectual property portfolio that currently consists of synthetic routes for the scalable production of pharmaceutical-grade psilocybin and psilocin (the active chemicals in psychedelic mushrooms) as well as their molecular precursors, analogs, and derivatives. These routes, in addition to a group of novel chemical entities, are captured in a Patent Cooperation Treaty Application (“PCT”) filed by Telescope in December 2021.
Telescope’s proprietary chemical manufacturing methods have several key advantages (Figure 1):
They require fewer synthetic steps than other available methods, reducing supply chain costs, waste streams, and investments in the isolation and purification of intermediate compounds. Shorter manufacturing cycles also accelerate deployment and help maintain a competitive position.
Unlike existing synthetic methods, we avoid the use of highly flammable chemicals that are prohibitively hazardous at a large scale.
We combine chemical manufacturing techniques that are standard practice in the pharmaceutical industry. This feature lowers the development costs to deploy our synthetic route and enables faster profitability.
Figure 1. Short, safe synthetic processes using industry-friendly methods (such as Telescope’s proprietary routes to psilocybin) provide significant economic benefits for commercial manufacturing.
Our manufacturing routes are purposely flexible and easily tunable to produce valuable compounds in the same chemical family (e.g., dimethyltryptamine, harmaline, miprocin, ibogaine, melatonin, lysergic acid diethylamide, serotonin, bufotenine, etc.). The routes can also be tailored to produce novel molecules that may increase the safety, potency, or bioactivity of new psychedelic therapeutics. Even if a specific chemical compound fails to achieve FDA approval or pass regulatory milestones, Telescope’s manufacturing route can rapidly pivot to target the next generation of psychedelic drug candidates.
Within the PCT application filed in December 2021, Telescope has also captured a set of novel chemical entities (“NCEs”) to build a proprietary library of psychoactive compounds. The newly discovered molecules may perform similarly or more efficiently than psilocybin or other psychedelic medicines, and may become candidates for preclinical development as next-generation therapeutics in the future (Figure 2). NCEs may display improvements in safety, potency, specificity, or tunability, for example. To evaluate this potential, Telescope will pursue biological testing of these proprietary compounds by third-party, world-leading neurochemistry experts. Initial testing will aim to establish the effectiveness of the NCEs relative to leading psychoactive candidates.
Figure 2. Telescope’s intellectual property portfolio includes a set of novel chemical entities in the same chemical family as psilocybin. These new compounds may pave the way for accessing the next generation of psychedelic therapeutics.
Telescope plans to expand this intellectual property moat over the next year to increase the scope of proprietary chemical reactivity and accessible products. The Company is also building relationships with biotechnology and pharmaceutical companies to explore avenues for monetization.
2. Increased in-house research capacity and proprietary research platforms
As of June 2021, Telescope occupies a dedicated laboratory facility in Vancouver, British Columbia. Here, we are developing and deploying our unique, proprietary ReACT platforms (Figures 3 and 4): robotic systems guided by artificial intelligence that increase the efficiency and quality of chemical research. We combine and integrate automation systems into a next-generation, self-guided chemistry experimentation platform that provides rapid, reliable data. This approach to research has enabled us to develop Telescope’s synthetic manufacturing processes for psilocybin in under one year.
ReACT is powered by our cross-disciplinary technical team of organic, process, and analytical chemists, computer scientists, and mechatronics engineers. The seamless integration of hardware, software, and chemistry knowledge is key to rapidly advancing Telescope’s technical goals.
Figure 4. A robotic arm module used in Telescope’s ReACT platforms.
Telescope’s high-level aim is to transform industrial research and development by deploying its automated platforms and chemical technology across the pharmaceutical and chemical manufacturing sectors. Over the next quarter, we aim to engage in consulting agreements and research contracts with specific, major global pharmaceutical and chemical manufacturing companies to apply our research platforms in industrial settings. These projects would generate near term cash flow while validating Telescope’s ability to break down process barriers and increase the efficiency of industrial R&D. We are also exploring relationships with global laboratory instrumentation and automation companies to commercialize Telescope’s automation platforms, aiming to manufacture, market, and sell these platforms over the next two years.
Telescope’s technical leadership comprises internationally renowned experts in chemical manufacturing and automation, having collectively authored over 450 academic publications and 33 patents.
Prof. Barry Sharpless (Senior technical advisor) received the Nobel Prize in Chemistry in 2001 for “the most important discovery in the field of synthesis during the past few decades”. He received the Priestley Medal (the highest honour in the American Chemical Society) in 2019 and is the W.M. Keck Professor of Chemistry at the Scripps Research Institute in La Jolla, California.
Prof. Jason Hein (CEO, Director) leads one of the largest academic chemistry research groups in Canada at the University of British Columbia. Has authored 50+ peer-reviewed articles amassing over 4,000 citations on organic chemistry, commercial manufacturing, and the role of automation, robotics and artificial intelligence in controlling pharmaceutical production.
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Our aim is to bring modern chemical solutions to meet the most serious challenges in human health.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.
Forward-looking statements in this document include expectations surrounding revenue streams from the research agreements, the patent filing process and the timing thereof, uses and viability of the intellectual property portfolio held by the Company, the performance of novel chemical entities, anticipated trends in the demand for psychedelic medical treatments and the ability of the intellectual property portfolio of the Company to respond to this demand, and all other statements that are not statements of historical fact.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; future legislative and regulatory developments involving psilocybin; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the psilocybin industry in Canada and generally; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Vancouver, BC — January 17, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI) announces that it has filed a Patent Cooperation Treaty (“PCT”) patent application for its scalable manufacturing methods to produce psilocybin and related tryptamine compounds. This application claims the priority date of a preceding provisional application filed with the United States Patent and Trade Office on December 31, 2020.
This PCT filing covers novel synthetic routes for the production of psilocybin and psilocin along with their precursors, analogs, and derivatives. These molecules belong to the tryptamine class of compounds that has been gaining momentum in the psychedelic medicine space in recent years. The processes outlined in this patent application are positioned to enable scalable manufacturing because they require fewer synthetic steps than current methods, utilize cost effective and readily available starting materials, and leverage chemical manufacturing processes that are already standard practice in the pharmaceutical industry. Telescope’s synthetic methods are therefore well-poised for compatibility with the standards of current Good Manufacturing Practices (cGMP) ultimately required for pharmaceutical deployment.
Jason Hein, CEO of Telescope, noted, “the demand for pharmaceutical-grade psilocybin and psychedelic tryptamines is rising. We are seeing increased numbers of trials and studies advancing these compounds along the drug development pipeline, but there has been relatively little focus on how these molecules will be reliably produced at a large scale. Telescope’s patent represents a significant milestone in addressing the impending manufacturing bottleneck.”
The synthetic processes described in the PCT application are not limited to the production of psilocybin, but enable access to a wide variety of tryptamines and can be easily adapted to produce specific derivatives. Derivatives are currently being explored by drug development companies seeking to tune the predictability, potency, or pharmacokinetic profiles of psychedelic therapeutics. Telescope’s intellectual property portfolio is therefore flexible and amenable to changing demands as different molecules are targeted throughout pharmaceutical development in the psychedelic space. Indeed, while developing proprietary synthesis processes, Telescope has discovered new molecules (Novel Chemical Entities; “NCEs“) that may become candidates for preclinical development. These NCEs are also captured within the PCT application.
“We’re very pleased with Telescope’s research results this year,” added Hein. “The Company is set up very well to continue developing our intellectual property portfolio and bringing our discoveries closer to deployment.”
About Telescope
Telescope is a chemical technology company developing scalable, widely deployable synthetic processes to manufacture pharmaceuticals for the treatment of mental health. The Company develops new enabling technology to achieve these goals, including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Research and development efforts are currently focused on medicines from the under-utilized tryptamine class of compounds, leveraging innovative process chemistry both to optimize synthetic procedures and access novel molecules. Our aim is to bring modern chemical solutions to meet the most serious challenges in human health.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.
Forward-looking statements in this document include expectations surrounding the patent filing process and the timing thereof, anticipated trends in the demand for psychedelic medical treatments and the ability of the intellectual property portfolio of the Company to respond to this demand, and all other statements that are not statements of historical fact.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; future legislative and regulatory developments involving psilocybin; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the psilocybin industry in Canada and generally; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Telescope Innovations (TELI) acquired the rights to the University of British Columbia’s research on synthetic psilocybin in exchange for 1M common shares at $0.99 each.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
